Short answer
Assembly Biosciences Inc (ASMB) filed its Q3 2014 10-Q quarterly report on Nov 17, 2014 for the quarter ended Sep 30, 2014.
Assembly Biosciences Inc Q3 2014 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales
- R&D expense $1.75M, down 51.52% YoY from $3.60M
- Worst expense trend: G&A stock compensation $5.51M, up 1,753.33% YoY
- Operating cash use $11.38M for nine months, financing provided $1.76M
- October financing added $14.9M; cash expected sufficient through Q2 2016, subject to development risks
Risk Factors
- No material changes to Item 1A risk factors identified in provided filing text
- Clinical development risk: HBV CpAM and CDAD programs remain preclinical or early-stage
- Regulatory risk: Future milestone payments total $825,000 under Indiana University HBV license
- Financial risk: Cash declined to $17,932,627 by September 30, 2014
- Acquisition risk: Preliminary Assembly merger valuation includes $30,137,350 indefinite-lived IPR&D and $12,142,702 goodwill
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Assembly Biosciences Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 5, 2019
- Q1 2019 10-QFiled May 9, 2019
- Q3 2018 10-QFiled Nov 8, 2018
- Q2 2018 10-QFiled Aug 8, 2018
- Q1 2018 10-QFiled May 7, 2018
- Q3 2017 10-QFiled Nov 1, 2017
- Q2 2017 10-QFiled Aug 9, 2017
- Q1 2017 10-QFiled May 8, 2017
- Q3 2016 10-QFiled Nov 9, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 10, 2016
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.